# A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

> **NCT04617275** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 151 (actual)

## Conditions studied

- Diabetes
- Obesity

## Interventions

- **DRUG:** PF-06882961
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04617275
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-06
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-11-17
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617275, "A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04617275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*